Symbols / DARE
DARE Chart
About
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 22.38M |
| Enterprise Value | 3.58M | Income | -17.46M | Sales | -57.13K |
| Book/sh | 0.20 | Cash/sh | 1.61 | Dividend Yield | — |
| Payout | 0.00% | Employees | 21 | IPO | — |
| P/E | — | Forward P/E | -4.74 | PEG | — |
| P/S | -391.67 | P/B | 8.10 | P/C | — |
| EV/EBITDA | -0.22 | EV/Sales | -62.62 | Quick Ratio | 1.10 |
| Current Ratio | 1.18 | Debt/Eq | 102.61 | LT Debt/Eq | — |
| EPS (ttm) | -1.83 | EPS next Y | -0.35 | EPS Growth | — |
| Revenue Growth | -94.60% | Earnings | 2026-03-30 | ROA | -44.74% |
| ROE | -25.43% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -1623.41% | Profit Margin | 0.00% | Shs Outstand | 13.48M |
| Shs Float | 13.04M | Short Float | 2.19% | Short Ratio | 3.87 |
| Short Interest | — | 52W High | 9.19 | 52W Low | 1.61 |
| Beta | 0.95 | Avg Volume | 150.77K | Volume | 112.31K |
| Target Price | $10.75 | Recom | None | Prev Close | $1.66 |
| Price | $1.66 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.75
Mean price target
2. Current target
$1.66
Latest analyst target
3. DCF / Fair value
$-1.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.66
Low
$8.00
High
$12.00
Mean
$10.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-09-04 | up | Maxim Group | Hold → Buy | $8 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-17 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-16 | main | Jones Trading | Buy → Buy | $13 |
| 2024-08-14 | down | Maxim Group | Buy → Hold | — |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-15 | up | Brookline Capital | Hold → Buy | $3 |
| 2024-05-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-04-17 | down | Brookline Capital | Buy → Hold | — |
| 2024-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-11-10 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-07-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-06-06 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-05-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-03-31 | reit | HC Wainwright & Co. | — → Buy | $7 |
- Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st Wed, 04 Feb 2026 08
- Daré Bioscience Receives FDA Clearance for Phase 2 Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection - Quiver Quantitative Mon, 23 Feb 2026 13
- Dare Bioscience launches preferred stock and warrant offering on Nasdaq - Investing.com hu, 29 Jan 2026 08
- Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance hu, 13 Nov 2025 08
- Don't You Dare Buy the Cheapest Cruise Line Stock - The Motley Fool Wed, 04 Feb 2026 08
- Don't You Dare Buy the Cheapest Cruise Line Stock - AOL.com ue, 24 Feb 2026 11
- Why Is Daré Bioscience Stock (DARE) Up 240% Today? - TipRanks Mon, 14 Jul 2025 07
- First-of-its-kind arousal cream for women offers US-wide telehealth access - Stock Titan Wed, 11 Feb 2026 08
- 2 Of The Market's Most Popular Stocks I Wouldn't Dare Buy Right Now - Seeking Alpha Sun, 31 Aug 2025 07
- I’m 44 with $400K in cash. I’m scared of a stock-market crash. Do I dare invest? - MarketWatch ue, 30 Sep 2025 07
- Dare Bioscience stock maintains Buy rating at H.C. Wainwright as Bayer exits - Investing.com ue, 02 Dec 2025 08
- Don't You Dare Buy the Cheapest Cruise Line Stock - Yahoo Finance Wed, 04 Feb 2026 08
- Daré Bioscience Launches First-Ever Sildenafil Cream for Women, DARE to PLAY™ Sildenafil Cream, Enhancing Female Arousal and Sexual Health - Quiver Quantitative Wed, 10 Dec 2025 08
- I Wouldn't Dare Buy These 3 Popular Investments Right Now - Seeking Alpha hu, 02 Oct 2025 07
- Earnings call transcript: Dare Bioscience Q3 2025 sees mixed stock reaction - Investing.com hu, 13 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -43.79M | -30.90M | -31.36M | -39.41M |
| TotalUnusualItems | 20.38M | 0.00 | 0.00 | 369.89K |
| TotalUnusualItemsExcludingGoodwill | 20.38M | 0.00 | 0.00 | 369.89K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.05M | -30.16M | -30.95M | -38.70M |
| ReconciledDepreciation | 42.33K | 38.36K | 24.20K | 26.41K |
| EBITDA | -23.41M | -30.90M | -31.36M | -39.04M |
| EBIT | -23.45M | -30.94M | -31.39M | -39.07M |
| NormalizedIncome | -24.43M | -30.16M | -30.95M | -39.07M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.05M | -30.16M | -30.95M | -38.70M |
| TotalExpenses | 23.46M | 33.75M | 41.39M | 39.07M |
| TotalOperatingIncomeAsReported | -23.45M | -30.94M | -31.39M | -39.07M |
| DilutedAverageShares | 8.50M | 7.28M | 7.05M | 5.10M |
| BasicAverageShares | 8.50M | 7.28M | 7.05M | 5.10M |
| DilutedEPS | -0.48 | -4.15 | -4.44 | -7.56 |
| BasicEPS | -0.48 | -4.15 | -4.44 | -7.56 |
| DilutedNIAvailtoComStockholders | -4.05M | -30.16M | -30.95M | -38.70M |
| NetIncomeCommonStockholders | -4.05M | -30.16M | -30.95M | -38.70M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -4.05M | -30.16M | -30.95M | -38.70M |
| NetIncomeIncludingNoncontrollingInterests | -4.05M | -30.16M | -30.95M | -38.70M |
| NetIncomeContinuousOperations | -4.05M | -30.16M | -30.95M | -38.70M |
| PretaxIncome | -4.05M | -30.16M | -30.95M | -38.70M |
| OtherIncomeExpense | 19.40M | 778.49K | 437.75K | 372.41K |
| OtherNonOperatingIncomeExpenses | -981.49K | 778.49K | 437.75K | 2.52K |
| SpecialIncomeCharges | 20.38M | 0.00 | 0.00 | 369.89K |
| GainOnSaleOfPPE | 20.38M | 0.00 | ||
| OtherSpecialCharges | -369.89K | |||
| OperatingIncome | -23.45M | -30.94M | -31.39M | -39.07M |
| OperatingExpense | 23.46M | 33.75M | 41.39M | 39.07M |
| OtherOperatingExpenses | 100.00K | 100.00K | 100.00K | |
| ResearchAndDevelopment | 14.21M | 21.54M | 30.04M | 30.62M |
| SellingGeneralAndAdministration | 9.16M | 12.11M | 11.24M | 8.45M |
| GeneralAndAdministrativeExpense | 9.16M | 12.11M | 11.24M | 8.45M |
| OtherGandA | 9.16M | 12.11M | 11.24M | 8.45M |
| TotalRevenue | 9.78K | 2.81M | 10.00M | 0.00 |
| OperatingRevenue | 9.78K | 2.81M | 10.00M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 8.70M | 8.33M | 7.07M | 7.00M |
| ShareIssued | 8.70M | 8.33M | 7.07M | 7.00M |
| TotalDebt | 1.30M | 1.40M | 488.74K | 270.55K |
| TangibleBookValue | -6.01M | -5.05M | 11.11M | 38.75M |
| InvestedCapital | -6.01M | -5.05M | 11.11M | 38.75M |
| WorkingCapital | -3.16M | -2.94M | 11.41M | 39.24M |
| NetTangibleAssets | -6.01M | -5.05M | 11.11M | 38.75M |
| CapitalLeaseObligations | 1.30M | 1.40M | 488.74K | 270.55K |
| CommonStockEquity | -6.01M | -5.05M | 11.11M | 38.75M |
| TotalCapitalization | -6.01M | -5.05M | 11.11M | 38.75M |
| TotalEquityGrossMinorityInterest | -6.01M | -5.05M | 11.11M | 38.75M |
| StockholdersEquity | -6.01M | -5.05M | 11.11M | 38.75M |
| GainsLossesNotAffectingRetainedEarnings | -428.81K | -360.90K | -351.31K | -154.97K |
| OtherEquityAdjustments | -428.81K | -360.90K | -351.31K | -154.97K |
| RetainedEarnings | -175.29M | -171.24M | -141.07M | -110.13M |
| AdditionalPaidInCapital | 169.71M | 166.55M | 152.53M | 149.03M |
| CapitalStock | 870.00 | 833.00 | 8.48K | 8.39K |
| CommonStock | 870.00 | 833.00 | 8.48K | 8.39K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 28.11M | 26.33M | 32.71M | 17.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.50M | 5.85M | 1.09M | 1.00M |
| OtherNonCurrentLiabilities | 4.75M | 3.91M | ||
| NonCurrentDeferredLiabilities | 1.00M | 1.00M | 1.00M | 1.00M |
| NonCurrentDeferredRevenue | 1.00M | 1.00M | 1.00M | 1.00M |
| LongTermDebtAndCapitalLeaseObligation | 754.38K | 935.74K | 90.35K | 0.00 |
| LongTermCapitalLeaseObligation | 754.38K | 935.74K | 90.35K | 0.00 |
| CurrentLiabilities | 21.61M | 20.48M | 31.62M | 16.05M |
| CurrentDeferredLiabilities | 16.56M | 13.74M | 18.30M | 10.54M |
| CurrentDeferredRevenue | 16.56M | 13.74M | 18.30M | 10.54M |
| CurrentDebtAndCapitalLeaseObligation | 548.64K | 468.73K | 398.39K | 270.55K |
| CurrentCapitalLeaseObligation | 548.64K | 468.73K | 398.39K | 270.55K |
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 805.61K | 805.41K | 1.72M | 1.53M |
| PayablesAndAccruedExpenses | 3.69M | 5.47M | 11.20M | 3.71M |
| CurrentAccruedExpenses | 1.99M | 1.81M | 9.17M | 1.60M |
| Payables | 1.71M | 3.66M | 2.03M | 2.10M |
| OtherPayable | 249.63K | 273.69K | ||
| AccountsPayable | 1.46M | 3.39M | 2.03M | 2.10M |
| TotalAssets | 22.10M | 21.28M | 43.83M | 55.81M |
| TotalNonCurrentAssets | 3.65M | 3.74M | 787.63K | 511.16K |
| OtherNonCurrentAssets | 1.10M | 599.59K | 254.29K | |
| NonCurrentPrepaidAssets | 12.03K | 1.16M | 10.50K | 125.44K |
| NonCurrentDeferredAssets | 139.20K | 143.00K | ||
| NetPPE | 2.54M | 1.98M | 522.83K | 242.71K |
| AccumulatedDepreciation | -175.89K | -145.70K | ||
| GrossPPE | 2.72M | 2.12M | 522.83K | 242.71K |
| Leases | 40.28K | 42.19K | ||
| ConstructionInProgress | 1.23M | 600.00K | ||
| OtherProperties | 1.41M | 1.43M | 522.83K | 242.71K |
| MachineryFurnitureEquipment | 37.24K | 51.98K | ||
| BuildingsAndImprovements | 1.21M | 1.32M | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 18.45M | 17.54M | 43.04M | 55.30M |
| PrepaidAssets | 2.52M | 6.12M | 6.67M | 2.48M |
| Receivables | 229.98K | 949.21K | 1.70M | 1.15M |
| OtherReceivables | 229.98K | 949.21K | 1.70M | 1.15M |
| CashCashEquivalentsAndShortTermInvestments | 15.70M | 10.48M | 34.67M | 51.67M |
| CashAndCashEquivalents | 15.70M | 10.48M | 34.67M | 51.67M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 4.82M | -39.49M | -18.15M | -28.78M |
| RepaymentOfDebt | -579.22K | -333.99K | 0.00 | |
| IssuanceOfDebt | 561.66K | 601.17K | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 453.58K | 9.35M | 1.22M | 75.31M |
| CapitalExpenditure | -573.05K | -629.43K | -63.07K | -14.52K |
| EndCashPosition | 16.00M | 10.81M | 34.67M | 51.67M |
| BeginningCashPosition | 10.81M | 34.67M | 51.67M | 4.67M |
| EffectOfExchangeRateChanges | -67.91K | -9.59K | -196.34K | -63.59K |
| ChangesInCash | 5.26M | -23.85M | -16.81M | 47.07M |
| FinancingCashFlow | 433.83K | 15.64M | 1.34M | 75.85M |
| CashFlowFromContinuingFinancingActivities | 433.83K | 15.64M | 1.34M | 75.85M |
| NetOtherFinancingCharges | -2.19K | 4.72M | ||
| ProceedsFromStockOptionExercised | 0.00 | 1.30M | 124.60K | 532.67K |
| NetCommonStockIssuance | 453.58K | 9.35M | 1.22M | 75.31M |
| CommonStockIssuance | 453.58K | 9.35M | 1.22M | 75.31M |
| NetIssuancePaymentsOfDebt | -17.56K | 267.19K | 0.00 | 0.00 |
| NetLongTermDebtIssuance | -17.56K | 267.19K | 0.00 | 0.00 |
| LongTermDebtPayments | -579.22K | -333.99K | 0.00 | |
| LongTermDebtIssuance | 561.66K | 601.17K | 0.00 | 0.00 |
| InvestingCashFlow | -573.05K | -629.43K | -63.07K | -14.52K |
| CashFlowFromContinuingInvestingActivities | -573.05K | -629.43K | -63.07K | -14.52K |
| NetPPEPurchaseAndSale | -573.05K | -629.43K | -63.07K | -14.52K |
| PurchaseOfPPE | -573.05K | -629.43K | -63.07K | -14.52K |
| OperatingCashFlow | 5.39M | -38.86M | -18.09M | -28.76M |
| CashFlowFromContinuingOperatingActivities | 5.39M | -38.86M | -18.09M | -28.76M |
| ChangeInWorkingCapital | 5.81M | -10.43M | 10.70M | 8.73M |
| ChangeInOtherWorkingCapital | 2.82M | -4.57M | 7.76M | 8.98M |
| ChangeInOtherCurrentLiabilities | -459.76K | 915.73K | ||
| ChangeInOtherCurrentAssets | -33.75K | -10.30K | 3.65K | 20.87K |
| ChangeInPayablesAndAccruedExpense | -1.24M | -6.91M | 7.68M | 1.04M |
| ChangeInAccruedExpense | 692.29K | -8.27M | 7.76M | -45.87K |
| ChangeInInterestPayable | 520.82K | 0.00 | ||
| ChangeInPayable | -1.93M | 1.36M | -75.13K | 1.08M |
| ChangeInAccountPayable | -1.93M | 1.36M | -75.13K | 1.08M |
| ChangeInPrepaidAssets | 4.00M | -605.26K | -4.19M | -622.34K |
| ChangeInReceivables | 719.23K | 753.95K | -557.84K | -685.15K |
| OtherNonCashItems | 788.32K | -837.42K | -23.06K | -51.85K |
| StockBasedCompensation | 2.20M | 2.53M | 2.16M | 1.60M |
| DepreciationAmortizationDepletion | 42.33K | 38.36K | 24.20K | 26.41K |
| DepreciationAndAmortization | 42.33K | 38.36K | 24.20K | 26.41K |
| Depreciation | 42.33K | 38.36K | 24.20K | 26.41K |
| OperatingGainsLosses | 600.20K | -369.89K | ||
| GainLossOnSaleOfPPE | 600.20K | 0.00 | ||
| NetIncomeFromContinuingOperations | -4.05M | -30.16M | -30.95M | -38.70M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DARE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|